Cerebral Venous Thrombosis after SARS-CoV-2 Infection and Pfizer-BioNTech Vaccination against COVID-19.
Martina NicolardiDaniele UrsoSilvia LuceriGiancarlo LogroscinoRoberto De BlasiPublished in: Diagnostics (Basel, Switzerland) (2022)
In the last 3 years, COVID-19 pandemic has produced great impacts on global population in terms of health and social costs. Pneumonia represents only one of several pathologies associated to COVID-19 disease. Among these, the cerebral venous thrombosis (CVT), constitutes an important cause of stroke. Here, we report a case of CVT diagnosed approximately 2 weeks after first dose of Pfizer-BioNTech vaccination, in a patient affected by COVID-19 few months earlier. He presented with headache and severe asthenia. The laboratory tests put in evidence thrombocytopenia and D-dimer elevation. A brain magnetic resonance imaging (MRI) and a computed tomography (CT) demonstrated hemorrhagic and ischemic phenomena on the right ventral thalamic nuclei, left thalamus, hippocampal and parahippocampal regions and the splenium of the corpus callosum. The study revealed a poorly opacified vein of Galeno and straight sinus. Heparin administration improved his clinical status; platelets values also arose over time.
Keyphrases
- coronavirus disease
- magnetic resonance imaging
- computed tomography
- sars cov
- cerebral ischemia
- contrast enhanced
- subarachnoid hemorrhage
- deep brain stimulation
- respiratory syndrome coronavirus
- healthcare
- positron emission tomography
- dual energy
- mental health
- public health
- image quality
- brain injury
- spinal cord
- blood brain barrier
- atrial fibrillation
- oxidative stress
- multiple sclerosis
- diffusion weighted imaging
- magnetic resonance
- risk assessment
- social media
- human health
- health promotion
- gestational age
- preterm birth
- spinal cord injury
- respiratory failure